{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T21:39:52Z","timestamp":1771969192764,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.urolonc.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T17:52:58Z","timestamp":1647539578000},"page":"274.e15-274.e23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder"],"prefix":"10.1016","volume":"40","author":[{"given":"Maheetha","family":"Bharadwaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumedh","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7338-8235","authenticated-orcid":false,"given":"Aaron","family":"Fleishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruslan","family":"Korets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2328-3421","authenticated-orcid":false,"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irving","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aria F.","family":"Olumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Gershman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.urolonc.2022.02.002_bib0001","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2005.04.005","article-title":"Vale, Claire L., Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.02.002_bib0002","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/annonc\/mdr354","article-title":"Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial","volume":"23","author":"Cognetti","year":"2012","journal-title":"Ann Oncol"},{"issue":"18_suppl","key":"10.1016\/j.urolonc.2022.02.002_bib0003","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.18_suppl.lba4518","article-title":"Randomized phase III trial comparing adjuvant paclitaxel\/gemcitabine\/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99\/01 study","volume":"28","author":"Paz-Ares","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.02.002_bib0004","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2022.02.002_bib0005","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.urolonc.2019.06.022","article-title":"Propensity-matched analysis of stage-specific efficacy of adjuvant chemotherapy for bladder cancer","volume":"37","author":"Chen","year":"2019","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.02.002_bib0006","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/0284186X.2017.1415461","article-title":"The role of adjuvant chemotherapy in locally advanced bladder cancer","volume":"57","author":"Haque","year":"2018","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.02.002_bib0007","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/jcm10040651","article-title":"Impact of adjuvant chemotherapy on survival of patients with advanced residual disease at radical cystectomy following neoadjuvant chemotherapy: systematic review and meta-analysis","volume":"10","author":"Krajewski","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.urolonc.2022.02.002_bib0008","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00432-014-1793-1","article-title":"Adjuvant chemotherapy after radical cystectomy for bladder cancer: a comparative study using inverse-probability-of-treatment weighting","volume":"141","author":"Kwon","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.02.002_bib0009","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","article-title":"Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.02.002_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-44504-9","article-title":"Adjuvant chemotherapy versus observation after radical cystectomy in patients with node-positive bladder cancer","volume":"9","author":"Pak","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.urolonc.2022.02.002_bib0011","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.clgc.2016.07.012","article-title":"Adjuvant chemotherapy after radical cystectomy for urothelial bladder cancer: outcome and prognostic factors for survival in a french multicenter, contemporary cohort","volume":"15","author":"Pouessel","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2022.02.002_bib0012","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamaoncol.2017.2374","article-title":"Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy","volume":"4","author":"Seisen","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.02.002_bib0013","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3233\/BLC-170107","article-title":"Use of adjuvant chemotherapy in patients with advanced bladder cancer after neoadjuvant chemotherapy","volume":"3","author":"Sui","year":"2017","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2022.02.002_bib0014","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.euf.2016.07.001","article-title":"Effectiveness of adjuvant chemotherapy after radical cystectomy for locally advanced and\/or pelvic lymph node-positive muscle-invasive urothelial carcinoma of the bladder: a propensity score-weighted competing risks analysis","volume":"4","author":"Vetterlein","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"11","key":"10.1016\/j.urolonc.2022.02.002_bib0015","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00345-016-1825-3","article-title":"Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy","volume":"34","author":"Zargar-Shoshtari","year":"2016","journal-title":"World J Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2022.02.002_bib0016","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2015.64.1076","article-title":"Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer","volume":"34","author":"Galsky","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2022.02.002_bib0017","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.6004\/jnccn.2018.0072","article-title":"NCCN guidelines insights: bladder cancer, version 5.2018","volume":"16","author":"Flaig","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"22","key":"10.1016\/j.urolonc.2022.02.002_bib0018","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2022.02.002_bib0019","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2022.02.002_bib0020","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.02.002_bib0021","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.fertnstert.2018.04.005","article-title":"Using observational data for personalized medicine when clinical trial evidence is limited","volume":"109","author":"Gershman","year":"2018","journal-title":"Fertil Steril"},{"issue":"19","key":"10.1016\/j.urolonc.2022.02.002_bib0022","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D'Agostino","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2022.02.002_bib0023","doi-asserted-by":"crossref","unstructured":"Harrell JFE. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. Springer; New York City, New York, 2015.","DOI":"10.1007\/978-3-319-19425-7"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922000369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922000369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:25:38Z","timestamp":1761042338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922000369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1078143922000369"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}